Goldenwell Biotech, Inc. has a newly reported beneficial owner: Ming Zhou received a gift of 20,000,000 common shares from Chief Executive Officer Shuang Liu on October 8, 2026, representing approximately 20.2% of the issuer’s common stock. Zhou was appointed a director that day. Goldenwell had 99,000,000 common shares issued and outstanding as of August 11, 2026.
Zhou says she holds the shares for investment purposes and may seek additional shares through open-market purchases if the stock is traded in the future, private transactions, or other means. She also reserves the right to dispose of shares and reports no present plan or proposal for the specified corporate or capital-structure actions.
Goldenwell Biotech, Inc. (GWLL) reports that director and 10% owner Ming Zhou directly holds 20,000,000 shares of common stock.
Goldenwell Biotech, Inc. (GWLL) appointed Ming Zhou as a director on October 8, 2026, bringing its board to four members. In connection with the appointment, Chief Executive Officer and director Shuang Liu gifted Zhou 20,000,000 common shares, equivalent to approximately 20.2% of the company’s issued and outstanding common stock. Zhou has served as managing director of Get Health Co., Ltd. and Get Intertrading Co., Ltd. since 2021. Her experience includes health products, nutritional supplements, herbal products, cosmetics, distribution, trading, warehousing and direct sales. She received an associate’s degree in Business Administration after attending China Central Radio and TV University from 1991 to 1993.
Goldenwell Biotech, Inc. dismissed Michael Gillespie & Associates, PLLC as its independent registered public accounting firm on September 27, 2026. The board had resolved on September 22, 2026, to engage Privatco CPA Limited as the new independent public accountants, and Privatco accepted.
The former auditor’s reports on the company’s 2025 and 2024 financial statements contained no adverse opinion or disclaimer and were not qualified or modified as to uncertainty, audit scope, or accounting principle. They stated substantial doubt about Goldenwell’s ability to continue as a going concern. Goldenwell reported no disagreements with the former auditor and no reportable events through the dismissal, and it had not consulted Privatco during the two most recent fiscal years or the interim period before the engagement.
Goldenwell Biotech, Inc. reported no revenue for the three- and six-month periods ended June 30, 2026 and remains a pre-revenue development-stage company. For the six months, it recorded a net loss of $54,482, an improvement from a $68,836 loss (as restated) in the prior-year period, driven primarily by modestly higher general and administrative expenses but some other income.
Total assets were $28,978, including cash of $11,143 and a prepaid OTCQB fee of $17,835. Total liabilities were $427,173, resulting in stockholders’ deficit of $(398,195) and working capital of $(398,195). The company has an outstanding related-party loan of $140,588 from its CEO and recognized $100,000 of unearned service revenue from a related-party contract.
Management disclosed an accumulated deficit of $1,710,598 and stated there is substantial doubt about the company’s ability to continue as a going concern. Operating cash outflows were $60,632 for the six months, partially offset by $45,000 of new related-party financing. Prior 2025 financial statements were restated for errors in revenue recognition, legal expense accruals and prepaid fee classification, and disclosure controls and procedures were concluded to be not effective.
Goldenwell Biotech, Inc. reported no revenue for the quarter ended March 31, 2026 and a net loss of $17,606, an improvement from a $38,536 loss a year earlier. Operating expenses were $31,335, partly offset by $15,829 of other income, including legal settlement and breakage income.
The company had cash of $13,414 and total assets of $18,754 against total liabilities of $380,073, resulting in stockholders’ deficit of $361,319. Management discloses substantial doubt about its ability to continue as a going concern, citing an accumulated deficit of $1,673,722 and dependence on raising additional capital.
Goldenwell estimates it needs about $5,000,000 to build manufacturing capacity and scale operations and plans to seek debt or equity financing, though no arrangements are in place. The company also restated prior 2025 quarterly figures to correct the timing of a $4,160 legal expense accrual.
Goldenwell Biotech, Inc. reports minimal 2025 revenue of $55 from nutraceutical and dietary supplement products and a net loss of $296,471, reflecting very early-stage operations. The company has no active operating facilities and uses its Ohio address only for mail.
As of December 31, 2025, Goldenwell held cash of $26,775, total assets of $36,120, total liabilities of $379,833, and a stockholders’ deficit of $343,713. Management and the auditor highlight substantial doubt about the company’s ability to continue as a going concern. Goldenwell estimates it needs about $5,000,000 and roughly one year to build manufacturing capacity, but currently relies on related-party loans and has three non-employee officers, material weaknesses in internal controls, no independent directors, and no formal cybersecurity risk processes.
Goldenwell Biotech, Inc. filed an amended quarterly report for the period ended September 30, 2025 to fully restate its financial statements after its auditor identified material GAAP errors. The restatement removed $25,000 of service revenue, added a $13,350 prepaid OTCQB fee asset, and adjusted legal fees, increasing Q3 2025 net loss from $7,985 to $27,895.
For the nine months ended September 30, 2025, the company reported no revenue and a net loss of $96,731, bringing its accumulated deficit to $1,456,377. At September 30, 2025, cash was $45,622, total assets were $233,760, total liabilities were $377,733, and stockholders’ equity was a deficit of $143,974. A related-party loan totaled $95,588, and management disclosed substantial doubt about the company’s ability to continue as a going concern.
Goldenwell Biotech, Inc. filed Amendment No. 1 to its quarterly report for the period ended June 30, 2025 to fully restate its financial statements and related disclosures. The restatement reverses previously recorded service revenue and reclassifies certain legal and OTC Markets fees to comply with US GAAP.
For the six months ended June 30, 2025, the Company generated no revenue and recorded a net loss of $68,836, bringing its accumulated deficit to $1,428,481. At June 30, 2025, Goldenwell reported cash of $76,507, total assets of $267,315, total liabilities of $383,393, and stockholders’ deficit of $116,079, and its auditors and management highlighted substantial doubt about its ability to continue as a going concern.
Goldenwell Biotech, Inc. filed an amended quarterly report to fully restate its financial statements for the quarter ended March 31, 2025 after determining earlier figures could no longer be relied upon. The restatement mainly records a previously unaccrued legal fee, increasing legal expense by $4,160 and raising the quarterly net loss to $38,536.
For the quarter, the company generated no revenue, incurred $36,436 in general and administrative costs and reported a basic and diluted loss per share of zero on 99,000,000 shares. Cash was $17,127 against current liabilities of $277,693, resulting in stockholders’ deficit of $85,778 and an accumulated deficit of $1,398,181.
Management discloses substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses, lack of revenue and reliance on capital raising. The company has a $95,599 related-party long-term loan and estimates it will need about $5,000,000 to build manufacturing capacity and scale its nutraceutical and supplement business.